Nasdaq GlobeNewswire

NovAtel® Demonstrates Precise Positioning Using the Teseo APP and Teseo V Automotive GNSS Chipsets from STMicroelectronics

Del

Deutsche Version: www.novatel.com/TeseoPRGerman

Calgary, Canada, March 06, 2018 (GLOBE NEWSWIRE) -- NovAtel, part of Hexagon's Positioning Intelligence Division, has integrated its high-precision positioning engine and correction services with the world's first automotive-grade multi-frequency GNSS chipsets, the STMicroelectronics Teseo APP (Automotive Precise Positioning) and Teseo V. The integration demonstrates future possibilities with regard to vehicle localization solutions. STMicroelectronics's Teseo APP and Teseo V provide multi-frequency GNSS data for PPP (Precise Point Positioning) and RTK (Real Time Kinematic) for accurate positioning capabilities. The Teseo APP features built-in integrity checking for use in safety-critical systems, whereas Teseo V is used for non-safety-critical precise positioning applications. NovAtel's positioning engine combines the GNSS measurements from these chipsets with Inertial Measurement Unit (IMU) data and Hexagon Precise Point Positioning (PPP) correction services on the demonstration platform to deliver centimeter-level PPP positioning solutions in real-time. 

"Working closely with STMicroelectronics using their Teseo APP chipset allowed us to innovate and speed up the development of our assured positioning solution tailored specifically for safe positioning of autonomous vehicles," said Jonathan Auld, VP Engineering and Safety Critical Systems from NovAtel.

NovAtel's positioning engine architecture enables a flexible integration with different GNSS receiver chipsets, IMUs, and processor environments, providing automotive manufacturers with additional flexibility when it comes to selecting components and subsystems of Advanced Driver Assistance Systems (ADAS) and autonomous driving solutions. The positioning engine is being developed to ASIL-B standards according to ISO26262 and will include a proprietary GNSS integrity solution to ensure safe positioning within defined protection limits that are tailored to the customer's application requirements. 

"NovAtel's choice of the automotive-quality ASIL-capable Teseo APP to integrate with their GNSS positioning engine is enabling them to develop a world-class safety-critical positioning offering to the automotive industry," said Antonio Radaelli, Director, Infotainment Business Unit, STMicroelectronics.

NovAtel technology continues to be an integral part of the connected and autonomous car ecosystems, including academic research, industry development, and real-life applications. Our automotive positioning solution includes automotive GNSS antenna technology, GNSS/INS positioning engine, and global correction services. Developed by the industry's most experienced team of high-performance, safety-critical GNSS/INS engineers.

Early results from the Teseo V demonstration platform are available now. To learn more, visit:

www.novatel.com/teseo-integration  

###

About NovAtel 

NovAtel designs, manufactures and sells high precision OEM positioning technology. Developed for efficient and rapid integration, our products have set the standard in quality and performance for over 25 years. State-of-the-art, lean manufacturing facilities in our North American headquarters produce the industry's most extensive line of OEM receivers, antennas and subsystems. All of our products are backed by a team of highly skilled application engineers.

NovAtel Inc. is part of Hexagon (Nasdaq Stockholm: HEXA B; hexagon.com), a leading global provider of information technology solutions that drive productivity and quality across geospatial and industrial landscapes.

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/978fa92c-fd66-4a77-9d7c-aeef5becdae7

http://www.globenewswire.com/NewsRoom/AttachmentNg/78e0fc9d-f134-4432-96bd-8b203dd3c5d2

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3db4147f-f366-4cc3-b772-66832f7c36df

Jennifer Abrahams, Marketing Manager
NovAtel
1.403.630.0382
jennifer.abrahams@hexagon.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NovAtel via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

World Conference on Lung Cancer Tuesday Press Conference: Improving the Cure Rate for Stage III Lung Cancer25.9.2018 19:26Pressemelding

TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC) featured some of the year’s most innovative research in both small cell and non-small cell lung cancer. Frances Shepherd, M.D., FRCPC, WCLC honorary chair, medical oncologist at Princess Margaret Cancer Centre and former president of the IASLC (2005-2007), opened with the practice-changing importance of data shared this morning at the 2018 Presidential Symposium. Dr. Shepherd continued with background on the current inoperability and low cure rate of Stage III lung cancers, which comprise 1/3 of all lung cancers. Ground breaking data presented during today’s symposium demonstrated an advancement in disease treatment not seen for many years. PACIFIC study shows durvalumab improves overall survival in patients with unresectable non-small cell lung cancer without progression after chemoradiotherapy Recent

Manufacturing Leadership Forum Will Highlight Enabling Industry 4.0 with Analytics25.9.2018 15:06Pressemelding

Upcoming Dates in Houston, Texas and Antwerp, Belgium PORTLAND, Ore., Sept. 25, 2018 (GLOBE NEWSWIRE) -- New dates for The Manufacturing Leadership Forum were announced today including Houston, Texas, US on October 9, 2018 at the Petroleum Club of Houston and on November 28, 2018 in Antwerp, Belgium at the Lindner WTC Hotel & City Lounge. The events are sponsored by Northwest Analytics, a leading provider of manufacturing intelligence and SPC software solutions for manufacturers. This premier manufacturing analytics educational event focuses on enabling Industry 4.0 programs with manufacturing analytics. The Forums will feature keynotes and case-study presentations from globally-recognized leaders in the application of manufacturing analytics. In its fourth year, The Manufacturing Leadership Forum will open with a keynote from analytics visionary, Dr. Lloyd Colegrove, Director of Data Services & Fundamental Problem Solving at The Dow Chemical Company. “The Manufacturing Leadership Foru

SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG Test25.9.2018 14:00Pressemelding

Test supports international guidelines for treating antibiotic resistant STI SYDNEY, Australia, Sept. 25, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus® MG (not available for sale in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen or MG, along with genetic markers linked to antibiotic resistance. In recent years, Mgen prevalence has increased globally and developed high rates of resistance to the common antibiotic treatment, azithromycin. "This test is an exciting new development that will increase the precision of patient care for patients impacted by Mycoplasma genitalium - a common sexually transmitted infection with limited treatment options,” notes Dr Maria Trent, Professor of Pediatrics and Public Health at Johns Hopkins Medicine. The SpeeDx ResistancePlus MG test is in use in laboratories acr

Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-10125.9.2018 14:00Pressemelding

Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Phase 3 trial in treatment-naïve EGFR mutation-positive NSCLC patients targeted to commence in 2019 NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that positive preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101 were presented yesterday in an oral presentation at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer in Toronto. The oral presentation included further details on, and updates from, the dataset announced previously. CK-101 is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being evaluated in advanced non

Novavax Initiates Phase 2 Clinical Trial of NanoFlu™ in Older Adults25.9.2018 13:00Pressemelding

First participants enrolled in Phase 2 clinical trial of quadrivalent NanoFlu formulations Top-line immunogenicity and safety data expected in the first quarter of 2019 Phase 2 results will support meeting with the U.S. Food and Drug Administration (FDA) and Phase 3 clinical trial design GAITHERSBURG, Md., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced the initiation of a Phase 2 dose and formulation confirmation clinical trial in older adults of NanoFlu, its nanoparticle seasonal influenza vaccine candidate. “Initiating this Phase 2 clinical trial of NanoFlu is an important milestone for Novavax,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “With top-line results expected in the first quarter of 2019, we plan to discuss these data with the FDA at an ‘End of Phase 2’ meeting and to agree on the appropriate Phase 3 clinical trial design to support licensure via accelerated approval. We continue to believe NanoFlu is a differen

CGAP Launches Photo and Video Contest Theme for 2018: Financial Inclusion in Africa25.9.2018 13:00Pressemelding

This year's CGAP contest is the first ever to accept short video entries WASHINGTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- The Consultative Group to Assist the Poor’s (CGAP) 13th annual photo contest, launched today, is seeking striking images on financial inclusion in Africa. For the first time, short video submissions on Africa also will be accepted. Entries may be submitted through December 14, 2018. Each contestant may submit up to 20 photos or videos to compete for the Grand Prize worth US$ 2,000. This year CGAP is looking for original and compelling photographs and short videos that tell the story of how financial services empower poor people and communities in Africa. The region is a center for financial innovation -- home to M-Pesa, the mobile money service launched a decade ago now replicated across markets worldwide; host to vibrant FinTech and e-commerce companies; and to a growing off-grid sector that leverages digital finance. Together these innovators contribute toward lifti

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom